Patients with low-risk chest pain have high utilization of stress testing and cardiac imaging, but low rates of acute coronary syndrome (ACS). The objective of this study was to determine whether the HEART score could safely reduce objective cardiac testing in patients with low-risk chest pain. Methods: A cohort of chest pain patients was identified from an emergency department-based observation unit registry. HEART scores were determined using registry data elements and blinded chart review. HEART scores were dichotomized into low (0-3) or high risk (Ͼ3). The outcome was major adverse cardiac events (MACE); a composite end point of all-cause mortality, myocardial infarction, or coronary revascularization during the index visit or within 30 days. Sensitivity, specificity, and potential reduction of cardiac testing were calculated. Results: In a span of 28 months, the registry included 1070 low-risk chest pain patients. MACE occurred in 0.6% (5/904) of patients with low-risk HEART scores compared with 4.2% (7/166) with a high-risk HEART scores (odds ratio ϭ 7.92; 95% confidence interval ͓95% CI͔: 2.48 -25.25). A HEART score of Ͼ3 was 58% sensitive (95% CI: 32-81%) and 85% specific (95% CI: 83-87%) for MACE. The HEART score missed 5 cases of ACS among 1070 patients (0.5%) and could have reduced cardiac testing by 84.5% (904/1070). Combination of serial troponin Ͼ0.065 ng/mL or HEART score Ͼ3 resulted in sensitivity of 100% (95% CI: 72-100%), specificity of 83% (95% CI: 81-85%), and potential reduction in cardiac testing of 82% (879/1070). Conclusions: If used to guide stress testing and cardiac imaging, the HEART score could substantially reduce cardiac testing in a population with low pretest probability of ACS.
A pproximately 8 to 10 million patients complaining of chest pain present to an emergency department (ED) annually in the United States. 1 The total cost of chest pain evaluations has been estimated at $5 to $10 billion annually, yet only about 10% of these patients are ultimately diagnosed with an acute coronary syndrome (ACS). [2] [3] [4] [5] The American College of Cardiology/American Heart Association guidelines suggest patients with symptoms consistent with ACS be stratified into low, intermediate, and high risk, and that serial markers and objective cardiac testing (stress testing or cardiac imaging) be performed on patients believed to be at low risk for ACS. These evaluations are commonly completed in an observation unit (OU) setting. However, OU cohorts at low risk for ACS have low major adverse cardiac event (MACE) rates, leading some to question the utility of stress in testing all low-risk patients. 6, 7 Unfortunately, clinical decision aids, such as the thrombosis in myocardial infarction (TIMI) risk score or Global Registry of Acute Coronary Events (GRACE) score, have lacked the sensitivity necessary to avoid additional diagnostic testing or inpatient care. 8, 9 To improve healthcare delivery, more accurate risk stratification is needed to properly select which patients are unlikely to benefit from objective cardiac testing.
The HEART score is a recently developed decision aid designed to identify ED patients, with chest pain or related symptoms, which can safely forgo objective cardiac testing. 10 It was recently retrospectively validated in a cohort of 910 patients presenting to European Cardiology Emergency Rooms, with undifferentiated chest pain. 11 In this study, patients with a low-risk HEART score (0 -3) had a MACE rate less than 1% at 6 weeks. 11 However, the HEART score has yet to be tested in patients presenting to an ED within the United States or among low-risk patients likely to be managed in a chest pain OU. It is possible that the HEART score could be used for incremental risk stratification in a similar way that the pulmonary embolism rule-out criteria is used in patients at low risk for pulmonary embolism. 12 By applying the HEART score to patients already identified as low risk for ACS, it may be possible to minimize missed MACE to an acceptable level and decrease the utilization of costly cardiac testing. The objective of this study is to determine whether the HEART score is predictive of MACE and to evaluate its potential for safely reducing objective cardiac testing in a United States ED cohort of low-risk chest pain patients.
METHODS

Study Design
This is a cohort study of patients included in the ED-based OU Chest Pain Registry at Wake Forest Baptist Medical Centre (WFBMC) between January 2008 and April 2010. Registry data elements include a combination of prospectively collected crosssectional data and retrospective data. The registry and this analysis were approved by the internal review board of the sponsoring organization; a waiver of consent was granted.
Study Setting and Population
WFBMC is a tertiary referral center with an annual ED volume of approximately 96,000 patients per year. Patients with chest pain suggestive of a cardiac etiology, but determined to be at low risk for ACS by TIMI risk score Ͻ2 and clinician assessment of low risk, were admitted to the ED-based OU and were included in the registry. Care providers were encouraged to use the the American College of Cardiology/American Heart Association framework for risk assessment. 13 Inclusion criteria for the registry include a normal or nondiagnostic ECG and negative first set of cardiac biomarkers (troponin I, CK-MB). The OU cares for 400 to 500 low-risk chest pain patients annually and is open 7 days a week, with 24-hour nursing and physician coverage. Patients admitted to the OU receive serial ECGs, serial cardiac biomarkers, and objective cardiac testing before discharge. The cardiac testing modality is at the discretion of the treating physician and consists of exercise stress echocardiogram, dobutamine stress echocar-diogram, coronary computed tomography angiography, or stress cardiac magnetic resonance. ECG stress tests without imaging are not performed at the study institution.
Study Protocol and Measures
Patients in the registry were queried for MACE, defined as a composite end point of all-cause mortality, myocardial infarction, or coronary revascularization during the index visit or within 30 days. Myocardial infarction was determined based on the 2000 Joint European Society of Cardiology/American College of Cardiology consensus definition, using an institutionally accepted troponin cutoff of 1.0 ng/mL (TnI-Ultra assay, Siemens, Munich Germany). 14 Coronary revascularization was defined as emergent or nonemergent revascularization procedures, including angioplasty with or without stent placement, or coronary artery bypass surgery. All patients in the OU registry receive a record review to determine MACE within 30 days. Potential objective cardiac testing reduction was assessed based on the premise that patients determined to be low risk by HEART score could forgo further objective cardiac testing. This was calculated by dividing the number of patients determined to be low risk by the HEART score by the total number of patients in the cohort. This represents the percentage of patients in the cohort that could have avoided cardiac testing if the HEART score was used to guide cardiac testing decisions.
A HEART score was determined for all patients in the registry. The methods for determining a HEART score have been previously described (Table 1) . 10, 11 Patients in the registry with incomplete or missing data elements required for calculation of a HEART score underwent a blinded chart review conducted by study investigators (S.M.,C.M.), using a standardized data collection tool.
Body mass index (BMI) was not included for calculation of the HEART score as height and weight were not routinely recorded in the ED or OU. Data abstraction was duplicated on 50 patients for calculation of interobserver agreement. The HEART score was calculated based on the initial troponin drawn in the ED and was considered positive if it was Ͼ1.0 ng/mL. At WFBMC, a troponin of 1.0 ng/mL was accepted as positive for acute myocardial infarction, values between 0.066 and 0.999 ng/mL were considered indeterminate, and values of Յ0.065 ng/mL were considered normal.
Statistical Analysis
The primary outcome measure was the presence or absence of MACE during the index visit or within 30 days. The predictor variable was the HEART score. Consistent with prior applications of the HEART score, this variable was dichotomized into low risk (0 -3) or high risk (Ն4). 10, 11 Univariate logistic regression was used to model the relationship between HEART scores and MACE. Sensitivity, specificity, positive and negative likelihood ratios, and potential cardiac testing reduction from use of the HEART score were calculated. A kappa statistic was generated to measure the interobserver agreement from HEART score data abstraction. A secondary analysis was conducted to determine the diagnostic accuracy of the combination of HEART score and a second serum troponin (obtained 4 -6 hours after ED admission) using a cutoff of 0.065 ng/mL (the upper limit of normal at WFBMC). The 4-to 6-hour troponin was tested in combination with the HEART score, based on a single post hoc hypothesis. Multiple comparisons with different variable combinations were not performed. Sensitivity analyses were performed to assess the potential impact of missing BMI data. First, obesity was added as a risk factor to 320 subjects (30% of the cohort) 15 using simple random selection without replacement. Second, because obesity was likely to coexist with other risk factors, an analysis was performed assigning obesity to all subjects with hypertension or diabetes. A third sensitivity analysis was performed adding obesity as a risk factor to all the patients in the cohort. An additional sensitivity analysis was performed to assess the rate of missed cases of ACS and potential reduction in cardiac testing if the cohort had a higher rate of MACE, by using the upper bound of the confidence interval of MACE rate. Statistical analysis was performed using SAS 9.2 (Cary, NC).
RESULTS
Between January 2008 and April 2010, 1070 low-risk chest pain patients, with normal or nondiagnostic ECGs and negative initial cardiac biomarkers, were included in the OU Chest Pain Registry at WFBMC. Characteristics of the cohort are summarized in Tables 2 and 3 . Of the 1070 patients, 532 required a chart review for missing data elements necessary for HEART score calculation. Interobserver agreement among blinded abstractors for HEART high versus low risk was excellent (kappa ϭ 0.81). Stress testing or cardiac imaging was completed in 93.7% (1003/1070) patients. Record review for MACE was completed on all registry patients with complete 30-day follow-up data available in 70% (753/1058) of the patients without index MACE (Figure 1 ).
MACE occurred in 1.1% (12/1070) of patients in the cohort. Among patients with a low-risk HEART score, 0.6% (5/904) (95% confidence interval ͓95% CI͔: 0.2-1.1%) had a MACE compared with 4.2% (7/166) (95% CI: 1.9 -8.6%) of patients with a high-risk HEART score (odds ratio, 7.92; 95% CI: 2.48 -25.25; P Ͻ 0.001). A high-risk HEART score (Ն4) was 58.3% sensitive (95% CI: 32-81%) and 85.0% specific (95% CI: 83-87%) for MACE with positive and negative likelihood ratios of 3.89 (95% CI: 2.36 -6.39) and 0.49 (95% CI: 0.25-0.96), respectively. The AUC for the Low risk ϭ 0 -3, high risk Ն4. Risk factors include currently treated diabetes mellitus, current or recent (Ͻ90 days) smoker, diagnosed and/or treated hypertension, diagnosed hypercholesterolemia, family history of coronary artery disease, obesity (body mass index Ͼ30), or a history of significant atherosclerosis (coronary revascularization, myocardial infarction, stroke, or peripheral arterial disease).
ECG indicates electrocardiogram.
HEART score was 0.72. Use of the HEART score to guide patient disposition would have resulted in 5 cases of missed ACS, a miss rate of less than 0.5% (5/1070; 95% CI: 0.2-1.1) and a potential reduction in cardiac testing of 84.5% (904/1070; 95% CI: 82-86.5%). Refer to Table 4 for a summary of the HEART score test characteristics. The combined use of a 4-to 6-hour serial troponin greater than 0.065 ng/mL or a high-risk HEART score resulted in 100% sensitivity, (95% CI: 72-100%) with a specificity of 83.1% (95% CI: 81-85%) and a potential cardiac testing reduction of 82.1% (879/1070; 95% CI: 80 -84%). See Table 5 for the test characteristics of the combined use of the HEART score and troponin testing. The sensitivity analyses for missing BMI data had little impact on the test characteristics of the HEART score (Table  A1) . If the rate of MACE increased to 2.0%, the miss rate of the HEART score for ACS would remain less than 1% and potential reduction in cardiac testing would remain high (Table A2) . Table 6 provides the clinical characteristics of the 12 patients with MACE.
DISCUSSION
The HEART score has recently been proposed as a method of risk stratification with the potential to define patients at very low risk, who are unlikely to benefit from further testing. This report examined the use of a HEART score in patients selected to receive an OU chest pain evaluation. This patient population poses the greatest diagnostic challenge to emergency physicians and is most likely to benefit from incremental risk stratification using a clinical decision aid, such as the HEART score.
The results of these analyses indicate that the HEART score has utility in further stratifying patients with symptoms suggestive of ACS after a care provider's clinical assessment of low risk. A high-risk HEART score was strongly associated with MACE (odds ratio, 7.92). However, exclusive reliance on the HEART score to determine the need for additional objective cardiac testing would have led to 5/1070 patients (0.5%) with a missed MACE. These results are consistent with the European multicenter validation study of the HEART score, which demonstrated a cardiac event rate of less than 1% in patients with HEART scores of Յ3. 11 The combined use of the HEART score with serial troponin testing to rule out MACE may be even safer.
Using the HEART score in our study population to select patients for objective cardiac testing demonstrated promise to reduce cardiac imaging and reduce potential for harm from diagnostic radiation. In patients stratified as low risk, based on an emergency physician's risk assessment and a TIMI risk score Ͻ2, using a HEART score of Ն4 to determine the need for cardiac testing would have reduced cardiac testing by 85%. At an average cost of $290 to $527 (US) per cardiac stress or imaging study, this practice would have resulted in a cost savings of approximately $262,160 to $476,408 at the study institution, during the 28-month study period. 16 In addition, as nearly a third of the patients in the cohort underwent coronary computed tomography angiography, reduced testing would have also decreased radiation exposure in the cohort. Even if the MACE rate was 2% rather than the 1.1% observed, assuming the same sensitivity and specificity, the potential cardiac testing reduction from using the HEART score would remain high and the missed ACS rate would remain less than 1%.
Although the potential reduction in objective cardiac testing using the HEART score is substantial, missing 0.5% of patients who will experience a MACE may not be acceptable. Given the potentially devastating outcome from missing a patient with MACE, high sensitivity is a critical characteristic of a chest pain decision aid. Unfortunately, the exclusive use of the HEART score lacked sensitivity (58.3%) and had only fair diagnostic accuracy (AUC ϭ 0.72).
With the aim of minimizing missed cases of MACE, we assessed the incremental value of adding serial cardiac biomarkers to the HEART score. In this cohort, combination of a high-risk HEART score or an elevated troponin at 4 to 6 hours from time of ED presentation was 100% sensitive for MACE. Despite a substantial increase in sensitivity, specificity and potential cardiac testing reduction remained high. These findings suggest that in properly selected low-risk patients, it is likely that the exclusion of myocardial infarction reduces post-test probability to an acceptable level without additional cardiac testing. The concept that stress testing is unlikely to be beneficial in some subsets of low-risk patients is consistent with a study by Hermann et al. 7 In aggregate, our findings suggest that the HEART score, when used with negative serial cardiac biomarkers, may be useful for identifying those patients who are least likely to benefit from cardiac testing.
LIMITATIONS
There are several limitations of this study. This study used patients included in an OU registry at a single medical center. WFBMS is a tertiary referral center, with an Emergency Medicine residency program, and an annual ED volume of approximately 96,000. The results of this study may not be generalizable to chest Critical Pathways in Cardiology • Volume 10, Number 3, September 2011 Can HEART Score Reduce Cardiac Testing pain patients presenting to other institutions. The decision to admit a patient to the OU was ultimately at the discretion of the emergency physician and therefore this cohort, by design, is a highly selected group. In addition, while the data elements from our registry could be used to determine HEART scores, this registry was not designed to determine HEART scores. Chart abstraction was necessary in 532 subjects to calculate a HEART score. Abstractors were blinded to patient outcomes in an attempt to minimize any intentional or unintentional bias. High interobserver agreement suggests that data abstraction was reliable. Also, the registry did not contain height and weight data necessary for BMI calculation. For this reason, BMI was not included in the risk score determination of the HEART score, which could have resulted in an underestimation of HEART score sensitivity and an overestimation of specificity. However, sensitivity analyses conducted to assess the potential impact of missing BMI data supported the inferences presented here. An additional limitation is that 6.3% of patients in this cohort did not receive stress testing or cardiac imaging as part or their OU care. The primary outcome measure in this study was MACE during the index visit or within 30 days, but 305 patients had only index data for MACE. This could have resulted in a misclassification bias and underestimation of the primary outcome. However, the likelihood of MACE occurring shortly after discharge in this cohort seems low. Nearly all patients received objective cardiac testing and of the patients with complete 30-day follow-up data, none had MACE that was not identified during the index visit. This is consistent with the literature, which has demonstrated that shortterm occurrence of ACS after discharge has been very low in patients receiving objective cardiac testing. 17 It is also possible that OU care and testing in this study resulted in changes to patients' medical management, which may have reduced the 30-day event rate in a way that is not accounted for in this analysis. However, even an increase in the rate of MACE to 2%, in our sensitivity analysis, had a negligible effect on potential reduction of cardiac testing while maintaining the rate of missed ACS Ͻ1%. Finally, our results regarding the combined use of an elevated 4-to 6-hour troponin or a high-risk HEART score should be interpreted with caution. This hypothesis was generated after testing the primary hypothesis regarding the sole use of the HEART score and requires further validation.
CONCLUSIONS
A high-risk HEART score is strongly associated with MACE in a population with a low pretest probability of ACS. Use of a low-risk HEART score to identify patients who do not require further ACS evaluation in this cohort would have resulted in missing MACE in 0.5% of patients. If used to guide objective cardiac testing, the HEART score could have substantially reduced cardiac testing in this cohort. Combining the HEART score with the results of 4-to 6-hour troponin testing may improve sensitivity without significantly decreasing specificity or the potential reduction in cardiac testing, but this approach requires validation.
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